Here's how the health tech investing industry has had to rethink investing amid a global pandemic. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

The coronavirus pandemic has upset countless industries, but if you zoom in on health tech you'll find a mix of opportunities and challenges for both health tech startups and investors.

On a virtual panel hosted by TMC Innovation and Ignite Healthcare Network, four female investors or founders discussed the health tech startup landscape. From advice for getting the attention of investors amid COVID-19 to inequities in health care and innovation, here's what the panel covered.

“I never thought I’d make an investment without meeting the founder face-to-face and visiting their site. The way I got comfortable with it was the opportunity was referred to me — it was a warm lead.”

— Karen Kerr, lead partner at Portfolia Rising America Fund. Kerr says those warm leads are more important now than ever, as is sharing a network.

“The first thing you need to do is understand our fund — or whatever fund you’re trying to go after — and pitch in a way that’s personal. You have to stand out from the beginning.”

— Kyra Doolan, managing director of Texas Halo Fund, says on reaching out to investors. She adds that she looks for a strong team, an innovative solution, a market need, and the terms of the deal. Meanwhile, red flags include if a startup says it has no competition, has unreasonable projections, is led by entrepreneurs who think they know everything, has an unwillingness to be upfront about COVID challenges, and doesn't have enough money in the bank.

“It’s important for companies to be upfront about the problems they’re facing — we all know these problems exist. Addressing that head-on with investors is a good way to go because having trust in a company you’re investing in is important.”

— Doolan continues on the importance of transparency between startup and investor.

“I’m looking for great entrepreneurs that are high integrity people. I’m looking to see that they really understand the industries they are in.”

— Kerr says on what she looks for in a founder. She adds that she tries to understand how they think and the advantages and disadvantages of their leadership are.

“You have to have the art of persuasion. You have this dream and vision — and there may not be anything there yet — but you need to be able to take people on this journey with you.”

— Damayanti Dipayana, CEO and co-founder of Manatee, a member of TMCx's 2020 cohort. She adds, representing the entrepreneur side of the table, that you really have to know yourself and your shortcomings.

“Any investor will look at it like if you can’t get the right people around and sell it to them, how are you going to uproot an industry.”

— Dipayana expands on the importance of growing your team and being persuasive.

“I think the pandemic has certainly shone a bright light on the inequities that exists, so solutions to these challenges are interesting things to think through.”

— Kerr says adding that the first investment from the Rising America Fund was into a fintech startup that serves underbanked communities.

“We’re seeing lower valuations maybe than we would have before this because the effects of this are going to go on for a long time, I would guess. Even when COVID starts to come down, the economic downturn is still going to exist.”

— Doolan says on where investment is at amid the pandemic.

“Ultimately if you want to have real bargaining power over your valuation, find other people who are interested.”

— Dipayana adds to the conversation about valuations. "If only one person interested, they are going to drive the valuation."

“Picking the right partners is such an important decision — don’t take that lightly just because they have money.”

—Chantell Preston, lead partner at Portfolio, co-founder and CEO of Facilities Management Group, and moderator of the event.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

Houston energy hub opens new fundraising cohort to fuel startups

Apply Now

EnergyTech Cypher has opened applications for its second Liftoff fundraising program.

Applications close May 20 for the 10-week virtual fundraising sprint. The program is geared toward energy and climatech founders preparing to raise their first institutional round. It will cover fundraising requisites, like pitch materials, term sheet negotiation and round closing, according to a release from EnergyTech Cypher.

The program kicks off June 1 and runs every Monday from 1-3 p.m. CST. It will conclude with an in-person capstone simulation in Houston on August 3, where founders will work to close a mock round.

Jason Ethier, EnergyTech Cypher founder and CEO, will lead the program with Payal Patel, an EnergyTech fellow and entrepreneur in residence.

The program is available through Cephyron, EnergyTech Cypher's new investor relationship management platform, built specifically for energy and climatech founders. Users must have a Cephyron Boost membership to participate in the Liftoff program.

The Cephyron IRM app recently went live and is available to founders at any point in their fundraising process, according to the news release. The platform aggregates investor data, tracks market signals and delivers curated weekly recommendations.

EnergyTech Cypher launched Liftoff last year. The inaugural cohort included 19 startups, including Houston-based AtmoSpark Technologies, The Woodlands-based Resollant and others. Each participant closed at least one fundraising deal, according to EnergyTech Cypher.

EnergyTech Cypher rebranded from EnergyTech Nexus earlier this year. It also launched its CoPilot accelerator in 2025. The inaugural group presented its first showcase during CERAWeek last month.

EnergyTech Cypher's annual Pilotathon Pilot Pitch and Showcase applications also opened this month. Find more information here.

---

This article originally appeared on EnergyCaptialHTX.com.

Cancer diagnostics startup wins top prize at annual Rice competition​

winner, winners

Rice University student-founded companies took home a total of $115,000 in equity-free funding at the annual Liu Idea Lab for Innovation and Entrepreneurship's H. Albert Napier Rice Launch Challenge last week.

2025 Rice Innovation Fellow Alexandria Carter won the top prize and $50,000 for her startup Bionostic. The startup offers personalized diagnostics for cancer patients by using 3D culturing through its Advanced Tumor Landscape Analysis System (ATLAS) platform.

Carter is working toward her PhD in bioengineering in Professor Michael King's laboratory. She recently completed the Rice Innovation Fellows program and plans to commercialize ATLAS, according to a news release from Rice.

Actile Technologies, founded by another former Rice Innovation Fellow, Barclay Jumet, won second place and $25,000. The company is developing and commercializing textile-integrated technologies. InnovationMap first covered Jumet's wearable technology back in 2023.

Kairos took home the third-place prize and $15,000, plus the $2,000 audience choice award and the $5,000 undergraduate business award. Founded last year by Sanjana Kavula and Adhira Tippur, Kairos is an AI-powered patient intake platform built specifically for independent dental practices.

The NRLC features top startups founded by undergraduate, graduate and MBA students at Rice each year. The top three finishers were named among a group of five finalists earlier this year, which also included HAAST Autonomous and Project Kestrel.

HAAST is developing an unmanned aircraft for organ transport, while Kestrel uses machine learning to organize bird photographers’ photo collections.

Teams presented multiple five-minute pitches throughout the application process over Zoom and in-person before the five finalists presented at the NRLC Championships April 21 at the Rice Memorial Center. Each finalist walked away with an equity-free investment.


Other awards went to:

UnitCode

  • $5,000 MBA Venture Award

HAAST Autonomous

  • $2,500 Chan-Kang Family Prize for Bold Ambition
  • $1,000 Healthcare Innovations Prize

Telstar Networks

  • $2,500 Outstanding Undergraduate Startup Award

Multiplay

  • $1,500 Frank Liu Jr. Prize for Creative Innovation in Music, Fashion, & the Arts

Butterfly Books

  • $1,500 Social Impact Award

SOOZ

  • $1,000 Interdisciplinary Innovation Prize sponsored by OURI

Dooly

  • $1,000 Consumer Goods Prize

Project Kestrel

  • $1,000 AI Prize

Veloci Running won the NRLC last year for its naturally shaped running shoe. Founder and CEO Tyler Strothman recently told InnovationMap that the company has gone on to sell roughly 10,000 pairs of its flagship Ascent shoe, designed to relieve lower leg tightness and absorb impact. Read more here.